Finance

Lists
Why is FAE down 2,24%?
Dive Deeper
FAE:BME
FAES Farma SA
4,80 €
-2,24%
(-0,11) 1D
13 ოქტ, 17:36:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for FAE...
Open
4,92 €
High
4,94 €
Low
4,76 €
Mkt. cap
1,52 მლრდ.
Avg. vol.
194,90 ათ.
Volume
163,97 ათ.
Dividend
2,67%
Quarterly dividend
0,03 €
Ex-dividend date
2 ივლ. 2026
P/E ratio
17,85
52-wk high
5,44 €
52-wk low
4,32 €
EPS
0,27 €
Shares outstanding
316,22 მლნ.
No. of employees
3 ათ.
Open
4,92 €
High
4,94 €
Low
4,76 €
Mkt. cap
1,52 მლრდ.
Avg. vol.
194,90 ათ.
Volume
163,97 ათ.
Dividend
2,67%
Quarterly dividend
0,03 €
Ex-dividend date
2 ივლ. 2026
P/E ratio
17,85
52-wk high
5,44 €
52-wk low
4,32 €
EPS
0,27 €
Shares outstanding
316,22 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
Profile
Faes Farma, originally Fábrica Española de Productos Químicos y Farmacéuticos, is a Spanish pharmaceutical company based in the Lamiaco district of Lejona in Biscay. Founded on 29 July 1933 by the Serra family with an initial capital of two million pesetas, it pioneered the development of various therapeutic compounds and has been listed on the Madrid Stock Exchange since the 1940s. Faes Farma’s headquarters, production facilities, and R&D center are located in Lejona, with additional offices in Madrid and Barcelona. The group also operates subsidiaries in Portugal, Italy, Mexico, Guatemala, Colombia, Chile, Peru, Bolivia, Ecuador and Nigeria, and maintains an animal nutrition and health division under the name FARM Faes. Wikipedia
About FAES Farma SA
CEO-
Employees2,61 ათ.
Founded29 ივლ. 1933
Headquarters-
SectorPharmaceutical industry
Last report
30 ივლ. 2026
Fiscal period
Q2 2026
0,09 € / -
0,00%miss
Revenue / Est. (EUR)
401,85 მლნ. / 189,65 მლნ.
+111,89%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
146,61 მლნ.
172,99 მლნ.
200,07 მლნ.
191,39 მლნ.
Cost of goods sold
52,40 მლნ.
73,44 მლნ.
61,59 მლნ.
60,25 მლნ.
Cost of revenue
52,40 მლნ.
73,44 მლნ.
61,59 მლნ.
60,25 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,36 მლნ.
80,84 მლნ.
45,67 მლნ.
44,06 მლნ.
Operating expense
68,06 მლნ.
98,44 მლნ.
100,13 მლნ.
98,54 მლნ.
Total operating expenses
120,47 მლნ.
171,88 მლნ.
161,72 მლნ.
158,78 მლნ.
Operating income
26,14 მლნ.
1,11 მლნ.
38,35 მლნ.
32,61 მლნ.
Other non operating income
401,00 ათ.
1,02 მლნ.
-
-
EBT including unusual items
25,18 მლნ.
-1,39 მლნ.
36,36 მლნ.
30,47 მლნ.
EBT excluding unusual items
25,18 მლნ.
-1,65 მლნ.
36,36 მლნ.
30,47 მლნ.
Income tax expense
3,75 მლნ.
-7,43 მლნ.
5,49 მლნ.
4,32 მლნ.
Effective tax rate
14,91%
534,46%
15,10%
14,19%
Other operating expenses
33,65 მლნ.
7,21 მლნ.
44,62 მლნ.
44,44 მლნ.
Net income
21,23 მლნ.
6,07 მლნ.
30,79 მლნ.
26,10 მლნ.
Net profit margin
14,48%
3,51%
15,39%
13,64%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
1,41 მლნ.
Interest expense
-1,99 მლნ.
-3,51 მლნ.
-1,99 მლნ.
-3,58 მლნ.
Net interest expenses
-1,99 მლნ.
-3,51 მლნ.
-1,99 მლნ.
-2,18 მლნ.
Depreciation and amortization charges
7,05 მლნ.
10,39 მლნ.
9,83 მლნ.
10,04 მლნ.
EBITDA
30,15 მლნ.
6,94 მლნ.
44,19 მლნ.
40,50 მლნ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები